| | | | |
CUSIP No. 55083R104 | | 13G | | Page 4 of 6 Pages |
Item 1(a). | Name of Issuer: |
Lyell Immunopharma, Inc.
Item 1(b). | Address of Issuer’s Principal Executive Offices: |
201 Haskins Way
South San Francisco, California
(a) – (c) | Name of Persons Filing; Address; Citizenship |
This statement on Schedule 13(G) is being filed jointly by the following persons, collectively, the “Reporting Persons”:
Address: c/o Trident Trust Company (B.V.I.) Limited, Trident Chambers, P.O. Box 146, Road Town, Tortola, British Virgin Islands
Citizenship: British Virgin Islands
| ii. | Milky Way Investments Group Limited |
Address: c/o Trident Trust Company (B.V.I.) Limited, Trident Chambers, P.O. Box 146, Road Town, Tortola, British Virgin Islands
Citizenship: British Virgin Islands
Item 2(d). | Title of Class of Securities: |
Common Stock, $0.0001 par value (“Common Stock”)
55083R104
The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The ownership percentages reported are based on 240,471,497 shares of Common Stock outstanding as of November 12, 2021, as reported by the Issuer in its 10-Q filed with the Securities and Exchange Commission on November 12, 2021.
Milky Way Investments Group Limited is controlled by MWG Management Limited, its corporate director.
Item 5. | Ownership of Five Percent or Less of a Class. |
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐.